Duodenal Mucosa Responses to Endoscopic Food Challenges in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome With Self-reported Food Intolerances: A Feasibility Study (DRFC)
Duodenal Responses to Food Challenges in Patients With Self-reported Food Intolerances: a Feasibility Study
The goal of this study is to investigate the feasibility of using intravenous fluorescein during a standard endoscopy-along with a laser to activate it and an optical filter-to identify changes in the duodenal mucosa after a controlled food challenge in individuals with IBD and IBS who experience food intolerances. The main questions it aims to answer are:
- Is this technique feasible approach to assess food intolerances in patients with IBD and IBS?
- Does patients with IBD and IBS exhibit acute tissue changes upon exposure to specific food antigens?
Researches will compare the food antigen to a placebo solution (saline solution without an antigen) to see if the reaction in the tissue is different.
Participants will:
- Answer questionnaires.
- Provide a blood and stool sample.
- Take an allergy test.
- Undergo an upper endoscopy.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, double-arm, randomized feasibility study. This study will recruit patients with Inflammatory Bowel Disease (IBD) in remission and patients with Irritable Bowel Syndrome (IBS), who self-report food intolerances. All participants will undergo an upper endoscopy with the administration of a food challenge solution (cow's milk protein or placebo), intravenous fluoresceine administration, biopsies and fluid collection.
Upon signing informed consent, participants will be enrolled in the study. Following enrollment, participants will be randomized in a 2:1 ratio to receive either a food challenge with a cow's milk protein solution or a placebo solution during the upper endoscopy, which will occur in visit 3.
During the first visit, participants will complete questionnaires covering demographics, medical history, gastrointestinal symptoms (using the Gastrointestinal Symptoms Rating Scale), and food intolerances. Blood samples will be collected from all participants, and IBD patients will additionally provide stool samples for fecal calprotectin measurement.
In the second visit, participants will be evaluated by an experienced allergologist, and a skin prick test will be conducted to rule out an allergy to cow's milk protein.
After completing these initial evaluations, participants will be scheduled for visit 3. In preparation for this visit, participants will be instructed to avoid consuming any products containing cow's milk for five days prior. During visit 3, an upper endoscopy will be performed. Through the endoscope's working channel, either a cow's milk protein solution or a placebo solution will be delivered to the third portion of the duodenum. Additionally, eight biopsies and a fluid sample will be collected from this area. A permeability test will also be performed using intravenous fluorescein, and the procedure will be recorded on video.
Following the third visit, a follow-up phone call will be conducted to assess any symptoms that participants may have experienced post-procedure.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: David Armstrong, MD
- Numero di telefono: 76404 905 521 2100
- Email: armstro@mcmaster.ca
Backup dei contatti dello studio
- Nome: Liam Rondeau, PhD
- Numero di telefono: 76404 19055259140
- Email: rondeaul@mcmaster.ca
Luoghi di studio
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster University Medical Centre
-
Investigatore principale:
- David Armstrong, MD
-
Contatto:
- David Armstrong, MD
- Numero di telefono: 76404 905 521 2100
- Email: armstro@mcmaster.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Confirmed diagnosis of IBD (UC or CD) and under clinical remission for at least 3 months, OR confirmed diagnosis of IBS (any subtype) by Rome IV criteria.
- Report having one or more food intolerance.
- Able to provide informed consent.
Exclusion Criteria:
- Presence of a known food allergy.
- Presence of serum IgE positivity or a positive skin-prick test to cow's milk.
- Known allergy to fluorescein.
- Diagnosis of celiac disease.
- Positive IgA TTG antibodies.
- Pregnancy or breastfeeding.
- Presence of a contraindication for an upper endoscopy.
- History of surgery involving the upper gastrointestinal tract.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Cow's milk protein solution
A solution with 5 mL cow's milk protein fraction mixed with 50% sterile water applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Altri nomi:
|
|
Comparatore placebo: Placebo solution
A solution with 18 mL sterile water + 2 mL simethicone applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Procedure completition
Lasso di tempo: From the start of the endoscopy up to 10 minutes after the food challenge
|
Successful completion of the procedure including sample collection, administration of the food challenge, and development of a reaction in the duodenal mucosa. A positive reaction in the mucosa will be defined by the presence of intraepithelial lymphocytes >25/100 epithelial cells. |
From the start of the endoscopy up to 10 minutes after the food challenge
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Segni e sintomi, Digestivo
- Malattie intestinali
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie del colon
- Gastroenterite
- Malattie del colon, funzionali
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Intolleranza alimentare
- Sindrome dell'intestino irritabile
- Malattie infiammatorie intestinali
- Tecniche investigative
- Gestione dei campioni
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Procedure chirurgiche minimamente invasive
- Tecniche citologiche
- Citodiagnosi
- Tecniche diagnostiche, chirurgiche
- Tecniche diagnostiche, sistema digestivo
- Endoscopia
- Procedure chirurgiche del sistema digestivo
- Biopsia
- Endoscopia, sistema digestivo
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 18305
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .